In prostate cancer (PCa), the use of new radiopharmaceuticals has improved the accuracy of
diagnosis and staging, refined surveillance strategies, and introduced specific and …

Metastatic Prostate Cancer (mPCa) is associated with a poor patient prognosis. mPCa
spreads throughout the body, often to bones, with spatial and temporal variations that make …

Purpose To combine peripheral blood indices and clinical factors in a prognostic score for
metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223 …

Simple Summary Advanced prostate cancer remains a clinical challenge, requiring novel
therapeutic treatments and biomarkers for patient-risk stratification. From a metabolic …

Purpose This study aimed to develop and assess an automated segmentation framework
based on deep learning for metastatic prostate cancer (mPCa) lesions in whole-body [68Ga] …

Simple Summary The huge armamentarium of currently available theragnostic modalities
allows a novel approach to prostate cancer from imaging to therapy. Clinical examination is …

Background: prostate-specific membrane antigen (PSMA) ligand PET has been recently
incorporated into international guidelines for several different indications in prostate cancer …

Aim To evaluate the relevance of incidental prostate [18F] FDG uptake (IPU) and to explore
the potential of radiomics and machine learning (ML) to predict prostate cancer (PCa) …

Objective The aim of this study was to determine the prognostic role of volumetric
parameters and Pro-PET scores obtained from 68 Ga-prostate-specific membrane antigen …

For prostate cancer (PCa) biochemical recurrence (BCR), the primarily suggested imaging
technique by the European Association of Urology (EAU) guidelines is prostate-specific …